Ishikawa S, Yura J, Shinagawa N, Mizuno A, Mashita K, Hori K
First Department of Surgery, Nagoya City University, Medical School.
Jpn J Antibiot. 1994 Jun;47(6):820-5.
The clinical efficacy of a new aminoglycoside antibiotic, arbekacin (ABK), was studied in surgical patients who had been infected with methicillin-resistant Staphylococcus aureus (MRSA). Six cases of pneumonia, 2 of wound infections and 2 of intra-abdominal infections were treated by ABK alone or ABK together with beta-lactam antibiotics such as imipenem/cilastatin or cefotiam. The overall clinical efficacies against these MRSA infections were excellent in one case, good in 6 and poor in 3. In six cases treated by ABK alone, good clinical responses were obtained in 4 cases. Among 4 cases that received combination therapy with ABK, good responses were obtained in 3 cases. No adverse reactions were found in ABK monotherapy or in combined therapy. These data suggested that ABK is an effective antibiotic on surgical infections caused by MRSA.
对一种新型氨基糖苷类抗生素阿贝卡星（ABK）在感染耐甲氧西林金黄色葡萄球菌（MRSA）的外科患者中的临床疗效进行了研究。6例肺炎、2例伤口感染和2例腹腔内感染患者单独使用ABK或ABK与β-内酰胺类抗生素（如亚胺培南/西司他丁或头孢替安）联合治疗。对这些MRSA感染的总体临床疗效，1例为优，6例为良，3例为差。在单独使用ABK治疗的6例患者中，4例获得了良好的临床反应。在接受ABK联合治疗的4例患者中，3例获得了良好的反应。ABK单药治疗或联合治疗均未发现不良反应。这些数据表明，ABK是治疗由MRSA引起的外科感染的有效抗生素。
